Registration and Breakfast

Sessions Open

Developments During The Last Decade

Looking at the last decade serial entrepreneur Andy Richards explores the good the bad and the 'not so' ugly! Every biotech company and it's top executive has good days and bad days, in this session we explore the implication of both of these days. Andy invites three key players in the industry to discuss their experiences.

Chairing the session:
Dr Andy Richards

• Mr Simon Sturge, CEO, Vernalis
• Mr Kieran Murphy, CEO, Whatman Plc
• Mr Ian Kent, Chairman, Argenta Discovery Ltd
• Mr Peter Chambre, Chairman, Alpharma API

Lunch

Bio-Medtech Convergence… Combination Products

Whatever the combination - diagnostic and drug, drug and delivery, or drug and therapy - getting the combination right is crucial for companies operating at the intersection of bio and medical technology. This session explores the latest developments in drug-device combinations, and seeks to uncover the pros and cons of the combination model.

Chairing the session:
Mr Tim Haines, Partner, Abingworth Management Ltd

• Dr Stephen Oesterle, Senior Vice President of Medicine and Technology, Medtronic
• John Poley, Pfizer Ltd
• Mr Peter Ehrenheim, President and CEO, GE Healthcare Life Sciences
• Mr Stuart Hendry, CEO, Sphere Medical
• Mr Geoff Smith,Senior Director, Illumina

Afternoon Break

The Future of Antibodies

After years of anticipation and encouraging responses to pathfinder products, monoclonal antibodies (mab) are now set to realise their true clinical and commercial potential. But what are the prospects for these products both for research and therapeutic use? In this session we hear from world leading companies which have pioneered mab development for therapeutics from humanised monoclonals to domain antibodies, we also hear from the next generation of mabs using modular antibody technology before learning how to develop a successful international business out of selling mabs for research purposes. Finally, the world leading antibody expert Greg Winter will give his closing remarks.

Chairing the session:

Dr Jonathan Lewis, Director of Business Development, Genentech

• Mr Bill Bertrand, Senior Vice President, Legal Affairs, General Counsel and Corporate Compliance Officer, MedImmune
• Dr Ian Tomlinson, VP, GSK Domantis Group, BioPharm CEDD
• Dr Gottfried Himmler, CEO, f-Star
• Dr Jonathan Milner, CEO, Abcam
• Sir Gregory Winter FRS, Acting Director, MRC Laboratory of Molecular Biology, Cambridge

Close of Session

• Gordon Baxter
• Professor Sir Chris Evans OBE

Celebration Dinner
Join our 10th Anniversary Party at the Wellcome Trust Genome Campus Restaurant – Murrays